All In Biotech

Drug Trial Radar · NCT02715804

A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Subjects With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma

Last checked: Nov 19, 2026Latest source record: Jul 14, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 492 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

492

Actual

Start

Mar 14, 2016

Primary completion

Nov 4, 2019

Study completion Nov 4, 2019

Sponsor

Lead sponsor
Halozyme TherapeuticsIndustry
Sponsor type
Industry
First posted
Mar 22, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the efficacy and safety of PEGylated Recombinant Human Hyaluronidase (PEGPH20) combined with nab-paclitaxel plus gemcitabine (PAG treatment), compared with placebo combined with nab-paclitaxel plus gemcitabine (AG treatment), in participants with hyaluronan (HA)-high Stage IV previously untreated pancreatic ductal adenocarcinoma (PDA).

Conditions

  • Pancreatic Ductal Carcinoma

Interventions

  • Biological: PEGylated Recombinant Human Hyaluronidase (PEGPH20)Other

    PEGPH20 will be administered as per the dose and schedule specified in the respective arms.

  • PlaceboDrug

    Matching placebo for PEGPH20

  • nab-PaclitaxelDrug

    Nab-paclitaxel will be administered as per the dose and schedule specified in the respective arms.

  • GemcitabineDrug

    Gemcitabine will be administered as per the dose and schedule specified in the respective arms.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall SurvivalTime frame: From randomization until death from any cause (maximum exposure: 150.1 weeks for PAG, and 83.9 weeks for AG)

Locations

217 sites in 22 countries. Site status is shown where the registry gives one.

  • University of South Alabama

    Mobile, Alabama

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona

  • Highlands Oncology Group

    Fayetteville, Arkansas

  • St. Jude Hospital Yorba DBA Linda St. Joseph Heritage Health

    Fullerton, California

  • Scripps Clinical Research Services

    La Jolla, California

  • Samuel Oschin Comprehensive Cancer Institute

    Los Angeles, California

  • David Geffen School of Medicine (DGSOM) at UCLA

    Los Angeles, California

  • Chao Family Comprehensive Cancer Center

    Orange, California

  • St. Joseph Hospital

    Orange, California

  • Desert Hematology Oncology Medical Group, Inc.

    Rancho Mirage, California

  • Cancer Care Associates Medical Group, Inc.

    Redondo Beach, California

  • Pacific Hematology Oncology Associates

    San Francisco, California

  • UCSF Helen Diller Family Comprehensive Cancer Center

    San Francisco, California

  • Pacific Central Coast Health Centers: San Luis Obispo Oncology and Hematology Health Center

    San Luis Obispo, California

  • St Joseph Heritage Healthcare

    Santa Rosa, California

  • Innovative Clinical Research Institution

    Whittier, California

  • Kaiser Permanente Franklin Medical Offices - Denver

    Denver, Colorado

  • US Oncology - Rocky Mountain Cancer Centers - Midtown

    Denver, Colorado

  • St. Mary's Medical Center

    Grand Junction, Colorado

  • Yale Cancer Center

    New Haven, Connecticut

  • MedStar Georgetown University Hospital

    Washington D.C., District of Columbia

  • Memorial Healthcare System - Memorial Cancer Institute

    Hollywood, Florida

  • 21st Century Oncology

    Jacksonville, Florida

  • MD Anderson Cancer Center Orlando

    Orlando, Florida

  • Fort Wayne Medical Oncology/Hematology, INC.

    Fort Wayne, Indiana

  • The University Of Kansas Cancer Center

    Kansas City, Kansas

  • University of Louisville

    Louisville, Kentucky

  • Ochsner Health Center

    Baton Rouge, Louisiana

  • Ochsner Clinic CCOP

    New Orleans, Louisiana

  • The Sidney Kimmel Comprehensive Cancer Center

    Baltimore, Maryland

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • UMass Memorial Medical Center

    Worcester, Massachusetts

  • University of Michigan Medical Center

    Ann Arbor, Michigan

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Virginia Piper Cancer Institute

    Minneapolis, Minnesota

  • University of Minnesota Medical School

    Minneapolis, Minnesota

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada

  • Renown Regional Medical Center

    Reno, Nevada

  • Dartmouth Hitchcock Medical Center

    Lebanon, New Hampshire

  • Saint Joseph's Ambulatory Clinic

    Clifton, New Jersey

Showing 40 of 217 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.